Show simple item record

dc.contributor.authorFerri, Valentina
dc.contributor.authorVicente, Emilio
dc.contributor.authorQuijano, Yolanda
dc.contributor.authorDuran, Hipolito
dc.contributor.authorDíaz, Eduardo
dc.contributor.authorFabra, Isabel
dc.contributor.authorMalave, Luis
dc.contributor.authorRuiz, Pablo
dc.contributor.authorCostantini, Giulia
dc.contributor.authorPizzuti, Giada
dc.contributor.authorCubillo, Antonio
dc.contributor.authorRubio Rodríguez, M. Carmen
dc.contributor.authorGarcía-Cañamaque, Lina
dc.contributor.authorNúñez Alfonsel, Javier
dc.contributor.authorCaruso, Riccardo
dc.date.accessioned2026-01-26T16:49:32Z
dc.date.available2026-01-26T16:49:32Z
dc.date.issued2023
dc.identifier.citationFerri, V., Vicente, E., Quijano, Y., Duran, H., Diaz, E., Fabra, I., ... & Caruso, R. (2023). Light and shadow of watch-and-wait strategy in rectal cancer: oncological result, clinical outcomes, and cost-effectiveness analysis. International Journal of Colorectal Disease, 38, 277. https://doi.org/10.1007/s00384-023-04573-9es
dc.identifier.issn1432-1262
dc.identifier.urihttp://hdl.handle.net/20.500.12020/1846
dc.description.abstractBackground The watch-and-wait (WW) strategy is a potential option for patients with rectal cancer who obtain a complete clinic response after neoadjuvant therapy. The aim of this study is to analyze the long-term oncological outcomes and perform a cost-effectiveness analysis in patients undergoing this strategy for rectal cancer. Material and methods The data of patients treated with the WW strategy were prospectively collected from January 2015 to January 2020. A control group was created, matched 1:1 from a pool of 480 patients undergoing total mesorectal excision. An independent company carried out the financial analysis. Clinical and oncological outcomes were analyzed in both groups. Outcome parameters included surgical and follow-up costs, quality-adjusted life years (QALYs), and the incremental cost per QALY gained or the incremental cost-effectiveness ratio (ICER). Results Forty patients were included in the WW group, with 40 patients in the surgical group. During a median follow-up period of 36 months, metastasis-free survival (MFS) and overall survival (OS) were similar in the two groups. In the WW group, nine (22%) local regrowths were detected in the first 2 years. The permanent stoma rate was slightly higher after salvage surgery in the WW group compared to the surgical group (48.5% vs 20%, p < 0.01). The cost-effectiveness analysis was slightly better for the WW group, especially for low rectal cancer compared to medium–high rectal cancer (ICER =  − 108,642.1 vs ICER =  − 42,423). Conclusions The WW strategy in locally advanced rectal cancer offers similar oncological outcomes with respect to the surgical group and excellent results in quality of life and cost outcomes, especially for low rectal cancer. Nonetheless, the complex surgical field during salvage surgery can lead to a high permanent stoma rate; therefore, the careful selection of patients is mandatory.es
dc.language.isoenes
dc.publisherSpringer-Verlag GmbH Germany, part of Springer Naturees
dc.titleLight and shadow of watch-and-wait strategy in rectal cancer: oncological result, clinical outcomes, and cost-effectiveness analysises
dc.typearticlees
dc.identifier.doihttps://doi.org/10.1007/s00384-023-04573-9
dc.journal.titleInternational Journal of Colorectal Diseasees
dc.page.initial277es
dc.page.final-es
dc.rights.accessRightsclosedAccesses
dc.subject.areaCiencias Biomédicases
dc.subject.keywordNeoadjuvant chemoradiotherapyes
dc.subject.keywordRectal canceres
dc.subject.keywordWatch-and-wait (WW) strategyes
dc.subject.unesco32 Ciencias Médicases
dc.volume.number38es


Files in this item

File/sSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record